You are here: Industry Insights > Tecentriq

News List

Affimed, Roche Explore AFM24, Tecentriq Combo contractpharma
February 04, 2021
Affimed N.V., a clinical-stage immuno-oncology company, entered a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq).
Roche’s Tecentriq/Avastin combo improves survival in liver cancer pharmatimes
January 14, 2021
Roche is planning to present updated data confirming that its immunotherapy combination, consisting of Tecentriq (atezolizumab) and Avastin (bevacizumab), improves overall survival (OS) in patients with a type of liver cancer.
Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq pharmaceutical-business-review
January 08, 2021
Roche has secured a breakthrough therapy designation from the US Food and Drug Administration (FDA) for tiragolumab plus Tecentriq (atezolizumab) to treat PD-L1-high non-small cell lung cancer (NSCLC).
Waylivra, Tecentriq and more accepted by SMC pharmatimes
November 11, 2020
The Scottish Medicines Consortium has published guidance on eight new medicines, accepting seven of those and rejecting one for use by NHS Scotland in its November meeting.
Roche obtains EC approval for Tecentriq/Avastin to treat liver cancer pharmaceutical-technology
November 05, 2020
Roche has obtained approval from the European Commission for Tecentriq (atezolizumab) and Avastin (bevacizumab) combination to treat adult patients with advanced or unresectable hepatocellular carcinoma (HCC).
Roche gets positive CHMP opinion for Tecentriq plus Avastin to treat liver cancer expresspharma
September 21, 2020
The recommendation from the CHMP is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in combination with Avastin reduced the risk of disease worsening or death.
Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma expresspharma
August 03, 2020
The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf helped people live longer without disease worsening or death.
Tecentriq misses mark in ovarian cancer trial pharmatimes
July 15, 2020
Roche and Genentech's Tecentriq (atezolizumab) has failed to hit its primary goal in a late stage trial involving patients with newly diagnosed advanced stage ovarian cancer.
Roche's Tecentriq shows promise in early triple-negative breast cancer pharmatimes
June 22, 2020
Roche's Tecentriq (atezolizumab) in combination with chemotherapy has improved treatment response in people with early triple-negative breast cancer (TNBC), raising hopes for a new therapeutic option for the condition.
Roche's Tecentriq/Avastin combo wins US approval pharmatimes
June 04, 2020
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer.

Previous page 1 2 3 4 5 6 7 Next page